Membrane-Active Amphipathic Peptide WRL3 with in Vitro Antibiofilm Capability and in Vivo Efficacy in Treating Methicillin-Resistant Staphylococcus aureus Burn Wound Infections

Mao, Zhi; Han, Jun; Chang, None Bingxue; Gao, Ling; Lu, Zhaoxin; Lü, Fang; Zhao, Haizhen; Bie, Xiaomei

doi:10.1021/acsinfecdis.7b00100

Cited by 47 publications

(38 citation statements)

References 46 publications

(84 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another peptide SAAP-148, formulated in ointment, effectively treated both acute and established (biofilm-associated) wound infections in mice caused by multi-drug resistant S. aureus and A. baumannii after a single 4 h treatment [ 71 ]. WRL3 also demonstrated antibiofilm activity against multi-drug resistant S. aureus infection using a MRSA-infected burn wound model [ 72 ]. WRL3 was found to be able to control proliferation of MRSA in wound tissue as well as reduce bioburden and provided a more favorable environment for wound healing.…”

Section: Antibiofilm Peptidesmentioning

confidence: 99%

Antibiofilm Peptides and Peptidomimetics with Focus on Surface Immobilization

2018

View full text Add to dashboard Cite

Bacterial biofilms pose a major threat to public health, as they are associated with at least two thirds of all infections. They are highly resilient and render conventional antibiotics inefficient. As a part of the innate immune system, antimicrobial peptides have drawn attention within the last decades, as some of them are able to eradicate biofilms at sub-minimum inhibitory concentration (MIC) levels. However, peptides possess a number of disadvantages, such as susceptibility to proteolytic degradation, pH and/or salinity-dependent activity and loss of activity due to binding to serum proteins. Hence, proteolytically stable peptidomimetics were designed to overcome these drawbacks. This paper summarizes the current peptide and peptidomimetic strategies for combating bacteria-associated biofilm infections, both in respect to soluble and surface-functionalized solutions.

show abstract

Section: Antibiofilm Peptidesmentioning

confidence: 99%

Antibiofilm Peptides and Peptidomimetics with Focus on Surface Immobilization

2018

View full text Add to dashboard Cite

show abstract

“…It is no longer associated only with healthcare‐associated infections, but has become a source of zoonotic infections . Currently, most MRSA infections are studied using the skin infection model . However, systemic MRSA infection is equally important in the clinical setting .…”

Section: Discussionmentioning

confidence: 99%

Effect and mechanism of citral against methicillin‐resistant Staphylococcus aureus in vivo

et al. 2019

View full text Add to dashboard Cite

BACKGROUND: Citral is an active component of many plant extracts, and it is a safe additive used in food and cosmetics. A previous study showed that citral has a good antibacterial effect against methicillin-resistant Staphylococcus aureus (MRSA) in vitro, but its in vivo anti-infective activity has not been studied. Anti-MRSA activity and the preliminary mechanism of citral against MRSA were investigated in MRSA-infected KM mice. The ED 50 was calculated using Karber's method. Groups were selected for inflammatory and oxidative stress level tests, and lung and liver tissues were counterstained with HE for detection of pathological changes. Cytokines and oxidative factors were evaluated using the ELISA method (one-way ANOVA computed using SPSS 19.0.). RESULTS: With the increase in the concentration of citral, the survival rate of MRSA-infected mice increased accordingly. The ED 50 values of citral for intramuscular injection and intragastric administration were 0.09 and 0.26 g kg −1 respectively. Citral significantly reduced cytokines (IL-1 , IL-6, TNF-) and oxidative factors (malondialdehyde and hydroxyl radicals) of MRSA-infected mice, whereas it increased gluthtione and superoxide dismutase levels. Citral can reduce the lung inflammatory infiltrates infected by MRSA. CONCLUSIONS: Citral exerted a dose-dependent anti-MRSA effect and ameliorated MRSA-induced abnormal changes in inflammation and oxidative stress. This indicates that citral has the potential for development as a new anti-MRSA drug. Histopathological examination of diseased tissueHistopathological changes in the lung and liver of mice were examined after hematoxylin and eosin staining (Figs 4 and 5). As shown in Fig. 4, mouse liver tissue did not show significant J Sci Food Agric 2019; 99: 4423-4429

show abstract

“…The formation of new blood vessels which also belongs to the second wound healing stage can be supported by AMPs as well. Tylotoin promoted angiogenesis by inducing endothelial cell tube formation (Mu et al, 2014 ), while CW49 up-regulated angiogenic proteins (Liu et al, 2014a ), WRL3 increased vascular endothelial growth factor production (Ma et al, 2017 ), and LL-37 mediated angiogenesis via formyl peptide receptor-like 1 (Koczulla et al, 2003 ).…”

Section: Amps For the Treatment Of Sstismentioning

confidence: 99%

Antimicrobial Peptides and Their Therapeutic Potential for Bacterial Skin Infections and Wounds

Brandenburg²,

2018

View full text Add to dashboard Cite

Alarming data about increasing resistance to conventional antibiotics are reported, while at the same time the development of new antibiotics is stagnating. Skin and soft tissue infections (SSTIs) are mainly caused by the so called ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) which belong to the most recalcitrant bacteria and are resistant to almost all common antibiotics. S. aureus and P. aeruginosa are the most frequent pathogens isolated from chronic wounds and increasing resistance to topical antibiotics has become a major issue. Therefore, new treatment options are urgently needed. In recent years, research focused on the development of synthetic antimicrobial peptides (AMPs) with lower toxicity and improved activity compared to their endogenous counterparts. AMPs appear to be promising therapeutic options for the treatment of SSTIs and wounds as they show a broad spectrum of antimicrobial activity, low resistance rates and display pivotal immunomodulatory as well as wound healing promoting activities such as induction of cell migration and proliferation and angiogenesis. In this review, we evaluate the potential of AMPs for the treatment of bacterial SSTIs and wounds and provide an overview of the mechanisms of actions of AMPs that contribute to combat skin infections and to improve wound healing. Bacteria growing in biofilms are more resistant to conventional antibiotics than their planktonic counterparts due to limited biofilm penetration and distinct metabolic and physiological functions, and often result in chronification of infections and wounds. Thus, we further discuss the feasibility of AMPs as anti-biofilm agents. Finally, we highlight perspectives for future therapies and which issues remain to bring AMPs successfully to the market.

show abstract

Membrane-Active Amphipathic Peptide WRL3 with in Vitro Antibiofilm Capability and in Vivo Efficacy in Treating Methicillin-Resistant Staphylococcus aureus Burn Wound Infections

Cited by 47 publications

References 46 publications

Antibiofilm Peptides and Peptidomimetics with Focus on Surface Immobilization

Antibiofilm Peptides and Peptidomimetics with Focus on Surface Immobilization

Effect and mechanism of citral against methicillin‐resistant Staphylococcus aureus in vivo

Antimicrobial Peptides and Their Therapeutic Potential for Bacterial Skin Infections and Wounds

Contact Info

Product

Resources

About